Ranbaxy Said To Have Partner For API Of Novartis Drug Diovan
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories reportedly has filed formulation details with U.S. FDA for valsartan, the API of Novartis’ hypertension drug Diovan based upon a partnership with another multinational drug maker.